Eurostars Project E!10918 SUBLYME, Biovica International AB. Targeting SUMOylation to treat resistant diffuse large B-cell lymphoma

Important results from the project

In the project, Biovica has measured cell proliferation (TK activity) with the technology platform DiviTum and evaluated anti-cancer effects of project partner UbiQ´s compounds (SUMOiQ candidates) in cells and mouse models. Results originating from both cancer cells and treated mice could be used by UbiQ as a decision basis for future development. The important purpose of using DiviTum to generate more knowledge and evidence of anti-cancer effects early in development, in preclinical models, has been achieved.

Expected long term effects

The results show that in preclinical models, TK activity provides early signals that the SUMOi substances evaluated do not have tumor growth-inhibitory effects. UbiQ can use this information for future development plans for their candidate SUMOi substances. Biovica is already planning and implementing new projects with other partners including DiviTum in early evaluation of new anti-cancer drugs in preclinical and clinical studies.

Approach and implementation

** Denna text är maskinöversatt ** Biovica measured thymidine kinase (TK) activity and deoxycytidine kinase (dCK) in cancer cells, (large-cell malignant lymphoma) and in treated mice with implanted tumor cells. The tested treatment was the substance SUMOi494, produced by the project partner UbiQ. Three different cell cultures from the project partner Technische Universität München, with biological replicates was analyzed. Results show no or little anti-cancer effect of the SUMOiQ candidates, however, anti-cancer effect was concluded for the reference substance doxorubicin.